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Within this short period of time, gene therapy has proceeded from the conceptual stage to
technology development and laboratory research, and finally to clinical trials for the treat-
ment of a variety of deadly diseases. Cardiovascular disease, cancer, and stroke are leading
causes of death worldwide. Despite advances in medical, interventional, radiation and surgical
treatments, the mortality rate remains high, and the need for novel therapies is great. Gene
therapy provides an efficient approach to disease treatment. Notable advances in gene ther-
apy have been made for genetic disorders, including severe combined immune deficiency,
chronic granulomatus disorder, hemophilia and blindness, as well as for acquired diseases,
including cancer and neurodegenerative and cardiovascular diseases. However, lack of an effi-
cient delivery system to target cells as well as the difficulty of sustained expression of trans-
genes has hindered advancements in gene therapy. Ultrasound targeted microbubble
destruction (UTMD) is a promising approach for target-specific gene delivery, and it has been
successfully investigated for the treatment of many diseases in the past decade. In this paper,
we review UTMD-mediated gene delivery for the treatment of cardiovascular diseases, cancer
and stroke.
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+ MODELGene therapy for genetic disorders
Gene therapy has been used successfully for the correction
of abnormalities of genes, which result in clinical disorders.
These treatments have corrected the disorders and clinical
symptoms as well as improved the quality of patient lives.
For example, in (1) severe combined immune deficiency
(SCID), commonly known as the bubble boy disease, chil-
dren are born without an effective immune system and will
succumb to infections outside of the bubble without a bone
marrow transplantation from a matched donor. A milestone
study representing the first case of a gene therapy “cure”,
or at least a long-term correction, for patients with this
deadly genetic disorder was conducted by investigators in
Italy. The therapeutic gene called adenosine deaminase
(ADA) was introduced into the bone marrow cells of SCID
patients, followed by transplantation of the genetically-
corrected cells back into the same patients. The immune
system was reconstituted in all treated patients without
noticeable side effects, and these children now live normal
lives with their families without the need for further
treatment.1 (2) Chronic granulomatus disorder (CGD) is a
genetic disease that weakens the immune system resulting
in susceptibility to bacterial and fungal infections that can
be fatal. Using gene transfer technologies similar to those
employed in the SCID clinical trial, investigators in Germany
treated two patients with CGD. They detected substantial
gene transfer in both individuals’ neutrophils which allowed
for the development of a large number of functionally-
corrected phagocytes and notable clinical improvement.2
(3) In hemophilia, patients are not able to produce blood
clots and thus suffer from external and internal bleeding
that can be life threatening. In a clinical trial conducted in
the United States, the therapeutic gene Factor IX was
introduced into the liver of hemophilia patients and
restored their ability to form normal blood clots. The
therapeutic effect, however, was short-lived because the
genetically-corrected liver cells were likely recognized as
foreign and rejected by the healthy immune systems of the
patients.3 This immune-mediated rejection is similar to
that which occurs after organ transplantation, and a cura-
tive outcome by gene therapy might be achievable with
immune suppression or alternative gene delivery strategies
currently being tested in phase I/II clinical trials. (4) Leb-
er’s congenital amaurosis (LCA) is a rare inherited retinal
disease that causes severe visual impairment in infancy or
early childhood with an incidence of approximately 1 in
80,000 people. LCA is characterized by nystagmus, sluggish
or absent pupillary responses, and severe vision loss or
blindness. Researchers at Moorfields Eye Hospital and Uni-
versity College London carried out the world’s first gene
therapy clinical trial for patients with RPE65 LCA and
demonstrated that the experimental treatment is safe and
can improve sight. These findings represent a landmark for
gene therapy technology and could have significant impact
on future treatments for eye disease.4
Gene therapy for acquired diseases
It is known that the onset of clinical disorders may be
related to genetic alterations. With the development ofPlease cite this article in press as: Wu J, Li R-K, Ultrasound-targeted m
diseases, Genes & Diseases (2016), http://dx.doi.org/10.1016/j.gendnew technologies, these genetic abnormalities have been
identified and have become new targets of gene therapy.
It has been demonstrated that some tumor formation are
highly correlated with genetic mutation or alteration. (1)
Cancer researchers have developed several different
strategies for utilizing gene therapy in the treatment of a
wide variety of cancers, including suicide gene therapy,
oncolytic virotherapy, anti-angiogenesis and therapeutic
gene vaccines. In fact, two-thirds of all gene therapy trials
are cancer based and many of these trials are entering an
advanced investigational stage, including a Phase III trial
of Ad.p53 for head and neck cancer5 and a Phase III gene
vaccine trial for prostate cancer.6 In the latter trial, use of
sipuleucel-T immunotherapy prolonged overall survival in
men with metastatic castration-resistant prostate cancer.
Additionally, numerous Phase I and Phase II clinical trials
for cancers in other organs are being conducted in aca-
demic medical centers and biotechnology companies using
novel technologies and therapeutics developed on-site. (2)
Stroke is the fifth leading cause of death and disability in
developed countries.7 The morbidity and mortality asso-
ciated with stroke result in severe social and economic
burden on patients and their family members. Gene
therapy could be applicable to the treatment of severe
stroke, and several experimental studies have revealed
the usefulness of gene therapy in the protection of neu-
rons against ischemia, reduction of infarct size, and
improvement of function.8e11 (3) Cardiovascular diseases
include coronary artery disease, heart failure, and cardiac
arrhythmias. Nabel et al were the first to carry out suc-
cessful gene therapy through the transfer of endothelial
cells for expression of recombinant genes in the cardio-
vascular system in 1989.12 Following this achievement,
gene therapy for cardiovascular diseases has been per-
formed worldwide. However, the effectiveness of gene
therapy for cardiovascular diseases has been modest
because of the lack of gene delivery techniques to provide
an adequate dose of a therapeutic gene to specific
targets.13
In the early phase of gene therapy, naked DNA such as
plasmids was directly injected into tissue. Because of
lower transfection efficiency, the effectiveness of these
treatments has been questioned. To improve transfection,
most gene therapy trials have relied on adenoviral-
associated platforms for gene delivery.14 Transfection ef-
ficiency has been improved significantly; however, the
safety of viral vectors and the need for repeated cathe-
terization raises significant safety issues for clinical trials.
Because of these concerns, clinical gene therapy is
currently limited to a few highly specialized Institutes.
Plasmid therapy, by comparison, is a universally accept-
able platform for safe gene delivery. However, DNA insta-
bility and the inability to deliver plasmids to specific sites
have hindered the application of this approach. A novel
gene delivery system is needed in gene therapy. Ultrasound
targeted microbubble destruction (UTMD) permits precise,
non-invasive gene delivery to target sites and increases
transfection efficiency as well as limits off-target trans-
fection.15e19 In this article, we review the most notable
advancements in gene therapy and the use of the UTMD for
gene delivery.icrobubble destruction in gene therapy: A new tool to cure human
is.2016.08.001
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Medical ultrasound is a commonly used non-invasive tech-
nique for clinical imaging. Ultrasound imaging uses high-
frequency sound waves to view real-time tissue or organs
inside the human body. It can also capture blood flowing
through blood vessels. Recently, microbubbles (MBs) have
been used in the medical field to enhance ultrasound im-
aging to monitor blood flow in tissue or organs. MBs are
small (less than 5 mm) gas-filled spherical voids that are
generally stabilized by a material coating composed of a
phospholipid or synthetic polymer (Fig. 1). The MBs act as
an ultrasound enhancer. In ultrasound examination, a
transducer (or probe) is placed directly on top of the tar-
geted tissue or organ. The transducer will produce a fre-
quency (usually 3.5 MHz) and receive an ultrasound signal
at 7 MHz, which will specifically show MBs. This technique
will reduce the signal from surrounding tissue, generating a
higher signal-to-noise ratio and improving imaging
significantly.
Due to recent advances in the preparation technology of
MBs and the innovations in ultrasound imaging, ultrasound
is no longer confined to the detection of tissue perfusion,
but extends to molecular imaging and targeted gene ther-
apy. The diagnostic and therapeutic potential of MBs can be
exploited using ultrasound. MBs are efficient reflectors of
ultrasound and excellent contrast agents for ultrasonic
imaging. MBs can also be used as carriers of therapeutic
genes. An ultrasound transducer can be placed on the tar-
geted tissue or organ for treatment. The ultrasound is able
to visualize MBs in the tissue or organ, and ultrasound en-
ergy can be employed to disrupt MBs, facilitating the tar-
geted release of therapeutic genes. The use of MBs as gene
vectors is based on the hypothesis that destruction of DNA-
loaded MBs by an ultrasound beam during their microvas-
cular transit through the target area will result in localized
transduction upon disruption of the MB shell while sparing
non-targeted areas. UTMD has a number of advantages as it
is target specific, highly effective, repeatable, non-
invasive, relatively low-cost, and does not require radia-
tion. It has been used to deliver genes to cells in vitro and
more recently has been used to deliver genes in vivo to
treat diabetes, cancer and cardiovascular diseases in
experimental animal models.15,20e25 UTMD provides a non-
invasive and non-viral method to effectively deliver plas-
mids to targeted organs.26,27Fig. 1 Schematics of three types of microbubbles (MBs). (A) De
increase gene carrying capacity. (C) Antibody-conjugated CMB to i
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Because of the visualization in vivo of targeted tissue or
organs and the ability to carry DNA, MBs in combination
with ultrasound have been hypothesized to be useful as a
targeted delivery system and therapy. Commercially avail-
able Definity MBs were first used as a carrier for therapeutic
genes in vivo, and were then combined with ultrasound MB
destruction to deliver therapeutic genes to the infarcted
heart. To investigate the feasibility of UTMD for gene de-
livery to the ischemic myocardium, we bound plasmid DNA
containing the green fluorescent protein (GFP) gene to
Definity MBs and used ultrasound to target the delivery of
the gene to the mouse myocardium. GFP gene expression
was observed in the targeted myocardium (Fig. 2), but
expression was not observed in other organs. Other groups
also used this MB to deliver genes to the salivary glands and
liver,28,29 suggesting that this technique is an effective
system for the delivery of therapeutic genes to targeted
tissue.
Another important factor affecting the ability of MBs to
provide targeted gene delivery is their carrying capacity.
One of the limitations of commercially available Definity
MBs is their weak cationic charge which limits their ca-
pacity for carrying negatively-charged agents, such as
plasmid DNA. This has been confirmed by in vivo studies
demonstrating modest gene transfection efficiency. To
improve the efficacy of UTMD, our group designed and
synthesized a novel cationic MB (CMB). By changing the
composition of the membrane material of the MBs, we
increased the cationic charge of the new CMBs.18 Charac-
terization of this CMB revealed a much higher zeta poten-
tial than the Definity MB. The CMB demonstrated both a
greater binding capacity and gene transfection efficiency
compared to the Definity MB. For instance, the CMB bound
70% more plasmid DNA than the Definity MB as evaluated in
in vitro studies.18 In the in vivo investigation, UTMD-
mediated gene delivery with the CMB enhanced both
transfection efficiency and gene expression in the heart
after ischemic injury. The therapeutic effect of the CMBs
was greater because of better gene delivery.18
The targeting technique for UTMD is based on the
transducer (or probe) targeting the tissue or organ, which is
precise and straightforward. However, an important factor
influencing the quantity of therapeutic gene delivery is thefinity MB (DMB). (B) Positively-charged cationic MB (CMB) to
ncrease targeting capacity.
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Fig. 2 Confocal microphotograph of mouse myocardial tissue after UTMD treatment to show the efficiency of gene transfection.
Five days after UTMD treatment, mouse myocardial tissue samples were immunostained with an antibody against green fluorescent
protein (GFP, green) with nuclear staining (Hoechst, blue). (A) Control mice were injected with empty plasmids. (B) GFP mice were
injected with plasmids expressing GFP (arrows). Magnification Z 600.
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interest. Another limitation of the UTMD gene delivery
technique is the wide distribution of lipid-shelled MBs in the
body which contributes to lower gene delivery efficacy as
the concentration of MBs in the area of interest is not high
enough to achieve biological effects.30,31 Additionally,
ultrasound-facilitated gene delivery to injured tissue con-
stitutes passive targeting. The specificity of MB delivery
could be enhanced by adding tissue-specific antibodies to
induce active targeting. Targeted MBs can be created by
binding target molecules such as a specific antibody or
ligand to the surface of MBs to enable specific tissue tar-
geting. This will result in accumulation of MBs at targeted
tissue and ultrasound destruction will increase the regional
level of the therapeutic molecules. To achieve this, our
group successfully conjugated tissue-specific antibodies in
pathological conditions. For example, after myocardial
ischemia-reperfusion injury, the injured myocardium will
express matrix metalloproteinase 2 (MMP2), which is
involved in matrix modulation and ventricular reconstruc-
tion. The regional elevation of MMP2 could be a target of
tissue therapy. We have conjugated an antibody against
MMP2 to the CMB and synthesized a new CMBMMP2 for tar-
geted delivery. A thiolated MMP2 antibody to the PEG
chains on the CMB surface was confirmed by fluorescence
microscopy. Our in vivo evaluation demonstrated that the
CMBMMP2 improved MB accumulation in the rat myocardial
infarct region, with 57% more contrast intensity compared
to the non-conjugated CMB. This technique has generated
greater gene transfection in injured tissue, and the findings
suggest that double targeting therapy using tissue-specific
MBs is feasible and has significant potential.19Gene therapy for cardiovascular diseases
Congestive heart failure (CHF) is a major health care
concern with a rising incidence, particularly in older
patients.32e34 Despite advances in medical, interventional,
and surgical treatments, the mortality rate remains high
and is primarily the result of maladaptive cardiacPlease cite this article in press as: Wu J, Li R-K, Ultrasound-targeted m
diseases, Genes & Diseases (2016), http://dx.doi.org/10.1016/j.gendremodeling that initiates progressive ventricular dilation,
wall thinning, and cardiac decompensation.35,36 These
deleterious processes are accelerated in the growing
number of aged patients making the discovery of new
therapies an urgent necessity. In preclinical studies, gene
and cell therapies were found to restore cardiac function
after an extensive myocardial infarction, but initial clinical
trials were disappointing.37e41 Low gene transfection effi-
ciency and low cell survival, especially in aged patients,
limited the beneficial effects of this therapy. Improved
methods of gene delivery and augmented cell survival are
required to make gene therapy for CHF a viable treatment
option for the aging population.
Our understanding of the molecular biology of the heart
has expanded dramatically in recent years. The mecha-
nisms involved in gene expression (mRNA), repression
(miRNA), and transcriptional regulation have been eluci-
dated and correlated with cardiac disease and/or recovery
of cardiac function following injury. Early clinical attempts
at gene therapy were focused on myocardial protection and
salvage using vascular endothelial growth factor (VEGF).
The goal was to stimulate endogenous angiogenesis to
rescue the ischemic zone. The results were initially posi-
tive, demonstrating improved short-term perfusion, but
failed to deliver long-term neovascularization for sustain-
able perfusion or prolonged functional cardiac
improvement.42e45 For example, it has been postulated
that VEGF promotes a mitogenic response in the endothe-
lium to sprout and form new tubes; however, angiogenic
tip-cell penetration requires concomitant increases in
extracellular matrix (ECM)-degrading enzymes.46 In addi-
tion, newly formed microvessels fail to mature with VEGF
stimulation and do not adequately incorporate the pericyte
and smooth muscle investiture required for vessel stability
because this process requires low VEGF levels and an in-
crease in angiopoietin and stromal derived factor.47
Recently, other gene therapy studies have been initiated
to examine the delivery of sarcoendoplasmic reticulum
calcium ATPase 2a (SERCA2a),48,49 hepatocyte growth fac-
tor (HGF),50,51 or a combination of VEGF and basic fibro-
blast growth factor (bFGF).52 A combinatorial approach toicrobubble destruction in gene therapy: A new tool to cure human
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findings suggest that gene therapy is a beneficial and
effective treatment; however, efficacy of the therapy fully
relies on targeted gene delivery, proper gene expression in
the therapeutic tissue, and persistence of biological
function.UTMD gene delivery technique for
cardiovascular diseases
For cardiovascular diseases, UTMD provides a non-invasive
and non-viral method to effectively deliver plasmids to
targeted areas.26,27 In addition, the limited endothelial
injury induced by MB destruction facilitates gene delivery
to the myocardium. Therefore, this non-invasive, repeat-
able and targeted technique is an effective means of
delivering therapeutic genes to the ischemic myocardium.
We have shown that the VEGF gene can be effectively
transfected into the ischemic myocardium by UTMD and
that this gene therapy improved regional perfusion. VEGF
gene transfection also stimulated cytokine production and
enhanced cardiac regeneration after injury.15 These results
suggest that UTMD can successfully deliver genes to the
ischemic heart and improve myocardial perfusion and
ventricular function. We also investigated the safety and
optimal conditions for repeated UTMD-mediated delivery of
therapeutic genes to the rat heart. Definity MBs were used
to repeatedly deliver stem cellemobilizing genes after
myocardial infarction. Repeated delivery enhanced gene
expression with minimal myocardial tissue injury and
resulted in better restoration of ventricular function
compared with a single treatment.16 Kobulnik et al
compared the effectiveness of UTMD-mediated versus
direct intramuscular injection gene delivery for therapeutic
angiogenesis. They found that both intramuscular injection
and UTMD-mediated delivery of the VEGF(165) gene pro-
duced significant increases in microvascular blood volume
and microvascular blood flow. Microvascular blood flow was
even greater in UTMD-treated than intramuscular injection-
treated animals.53 Another group also tested a new gene
delivery strategy using direct intramyocardial injection of
the HGF gene in conjunction with MBs and UTMD. This de-
livery method enhanced gene expression by more than 10-
fold in dogs with myocardial infarction.17
We subsequently carried out in vivo studies to assess the
ability of the CMB to deliver the therapeutic AKT gene to
the ischemic rat myocardium. AKT transfection with the
CMB increased stem cell homing and enhanced tissue repair
and regeneration, which resulted in reduced infarct size,
increased infarct thickness, reduced apoptosis, increased
vascular density, and improved cardiac perfusion and
function compared to the Definity MB.18 Lee et al also used
CMBs to investigate anti-apoptotic gene therapy with
UTMD-mediated plasmid delivery of survivin, an inhibitor of
an apoptosis protein, to prevent apoptosis and to attenuate
left ventricular (LV) systolic dysfunction in a model of heart
failure induced by doxorubicin. They demonstrated that LV
fractional shortening (%) assessed by echocardiography and
systolic function assessed by pressure-volume loops were
greater in animals treated with survivin than those treated
with an empty vector or control animals. They also showedPlease cite this article in press as: Wu J, Li R-K, Ultrasound-targeted m
diseases, Genes & Diseases (2016), http://dx.doi.org/10.1016/j.gendithat relative to the other experimental groups, survivin-
treated animals had reduced apoptosis as measured stain-
ing for TUNEL, caspase activity and interstitial fibrosis.54
Thus, UTMD therapy using the CMB provides an efficient
platform for the enhanced delivery of factors required to
regenerate the ischemic heart and preserve cardiac
function.
To enhance the ability of this gene delivery method to
specifically target a region of interest, UTMD-mediated
CMBMMP2 delivery of the metalloproteinase 3 (Timp3) gene
was employed in a rat ischemia/reperfusion injury model.
This study demonstrated significantly increased TIMP3
protein levels in the infarct scar and border zones 3 days
post-UTMD gene delivery compared to levels found
following delivery by the non-conjugated CMB. Increased
levels of TIMP3 protein caused a reduction in MMP2 and
MMP9 activities which resulted in smaller and thicker in-
farcts and improved cardiac function.19 Recently, Deng and
colleagues developed a target MB (TMB) carrying an anti-
intercellular adhesion molecule-1 (ICAM-1) antibody to
selectively adhere to the ischemic vascular endothelium.55
Using this TMB, they investigated the feasibility and effi-
cacy of UTMD-mediated delivery of the angiopoietin-1 (Ang-
1) gene to the infarcted myocardium. They demonstrated
that the ICAM-1 TMBs selectively adhered to the ischemic
vascular endothelium in the infarct area of rabbits with
acute myocardial infarction. Ventricular function was bet-
ter and myocardial perfusion and microvascular density in
the infarct area were greater in the TMB group two weeks
after delivery of the Ang-1 gene compared with the non-
TMB group. UTMD therapy with TMBs provides an efficient
platform for the specific targeted delivery of factors
intended to enhance angiogenesis and improve cardiac
function after ischemic injury. This may provide a novel
strategy for future gene therapy.Gene therapy for cancer
Current therapies for cancer include surgery, radiation
therapy, chemotherapy, immunotherapy, and gene ther-
apy. Radiation therapy can cause side effects as it not only
kills or slows the growth of cancer cells, but can also
adversely affect nearby healthy cells. Chemotherapy is
known to have widespread systemic side effects because in
addition to killing fast-growing cancer cells, it also kills or
slows the growth of healthy cells that grow and divide
quickly. Immunotherapy including the use of monoclonal
antibodies has the potential for systemic and specific killing
of tumor cells. However, if the antibody is specific to a
single tumor antigen, tumor evasion can still occur by
down-regulation of that antigen.
Gene therapies have been shown to be effective for
certain cancers.56,57 Suicide gene therapy is one of the
most attractive anti-cancer strategies. The most commonly
used suicide gene, herpes simplex viruse1 thymidine kinase
(HSVtK), in conjunction with ganciclovir (GCV), has been
studied for use in gene therapy for cancer in several clinical
trials.58,59 Although gene therapy provides an alternative
strategy for the treatment of cancer, its application in the
clinic remains limited primarily due to the lack of a safe and
efficient gene delivery system.60 For example, previousicrobubble destruction in gene therapy: A new tool to cure human
s.2016.08.001
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vectors directly into the tumor, which is not always tech-
nically feasible and limits the possibility of repeated
treatments. Currently, viral vectors are the favored clinical
approach, but transduction of non-target tissues may occur,
resulting in adverse side effects.61 Furthermore, viral vec-
tors can elicit an immune response that could limit their
effectiveness and prevent repeated delivery.62 Thus, an
ideal gene therapy method for cancer treatment would be
non-viral and capable of specifically targeting and
destroying tumor cells after delivery while leaving healthy
tissue and organs unaffected.UTMD gene delivery technique for cancer
UTMD is emerging as a new gene therapy technique that
may overcome some of the limitations of the viral gene
delivery systems.20,21 Because this non-invasive, site-spe-
cific, non-viral approach to gene delivery could have sig-
nificant value for treating tumors, researchers have begun
to evaluate it using in vivo tumor models. This research has
focused on the suicide gene HSVtK,22,63e65 short antisense
oligodeoxynucleotide targeting the human androgen re-
ceptor to treat prostate tumours,66 gene therapy targeting
apoptosis,67,68 and anti-angiogenic gene therapy to sup-
press neovascularization in tumors.69,70
Carson et al were among the first to report the use of
intravenous injection of plasmid-loaded MBs and UTMD to
treat malignant tumors. They tested the hypothesis that
UTMD would specifically transduce tumor tissue and slow
tumor growth when treated with HSVtK and GCV. As a first
step, they demonstrated that UTMD-mediated delivery of
reporter genes resulted in tumor expression of luciferase
and GFP in perivascular areas and individual tumor cells.
Then they showed that the doubling time of HSVtK-treated
tumors was longer than GFP-treated control tumors and
accompanied by increased apoptosis and more areas of
cellular drop-out. Their data indicate that UTMD gene
therapy can transduce solid tumors and mediate a thera-
peutic effect. Therefore, UTMD is a promising non-viral
method of targeted gene therapy that may be useful in a
spectrum of tumors.22
Recently, our group evaluated gene therapy targeting
hepatocellular carcinoma (HCC) using the HSVtk/GCV sui-
cide gene system. We further investigated the synergistic
antitumor effect of co-delivery of the angiogenesis inhibi-
tor of tissue inhibitor of metalloproteinase 3 (Timp3) gene.
We demonstrated that the cell viability of cancer cells
transfected with the HSVtk or Timp3 gene was reduced by
>40% compared cancer cells transfected with the vector
control. Cell viability was further inhibited by over 50% with
co-transfection of the two genes. UTMD-mediated delivery
of HSVtk or Timp3 suppressed tumor growth by >45% and
increased the survival of tumor-bearing animals. Co-
delivery of these two genes resulted in a further 30%
improvement in tumor suppression and significant exten-
sion of animal survival. Furthermore, UTMD gene delivery
increased the number of apoptotic cells and decreased the
vascular density of tumors. Thus, targeted co-delivery of
these two genes synergistically improved their antitumor
effects and could provide an effective therapy for HCC.23Please cite this article in press as: Wu J, Li R-K, Ultrasound-targeted m
diseases, Genes & Diseases (2016), http://dx.doi.org/10.1016/j.gendBesides its use for the delivery of DNA for cancer gene
therapy, UTMD could also be used to deliver gene silencing
factors to tumors. Fujii et al performed UTMD of vascular
endothelial growth factor receptor-2 (VEGFR2) short
hairpin (sh)RNA plasmid in an heterotopic mammary
adenocarcinoma model in rats. They evaluated pulsing in-
tervals (PIs) of 2, 5, 10, and 20 s. They demonstrated that
UTMD with a PI of 10 s resulted in the greatest knockdown
of VEGFR2 evaluated by PCR, immunostaining and Western
blotting. This knockdown resulted in smaller tumor volumes
and perfused areas and less tumor microvascular blood
volume and flow than the scrambled-plasmid control. They
concluded that for anti-VEGFR2 cancer gene therapy with
UTMD, a PI of 10 s results in greater target knockdown and a
more pronounced anti-angiogenic effect.24 Carson and
colleagues also investigated the effect of UTMD to enhance
the delivery of EGF receptor (EGFR)-directed siRNA to
murine squamous cell carcinomas. In in vitro analyses,
UTMD-mediated delivery of MBs loaded with EGFR-directed
siRNA reduced EGFR expression and EGF-dependent squa-
mous carcinoma cell growth. In the in vivo studies, serial
UTMD-mediated delivery of EGFR siRNA to squamous cell
carcinomas decreased EGFR expression and increased
tumor doubling time. These results offer preclinical proof-
of-concept for the use of UTMD to deliver gene-targeted
siRNA for cancer therapy.25Gene therapy for stroke
The current clinical management for stroke includes
thrombolytic therapy, percutaneous intravascular in-
terventions, behavioral rehabilitation strategies, and
medication such as aspirin. The application of thrombolytic
therapy is limited by a narrow time window (within 3 h after
acute stroke onset) and there is a risk of serious hemor-
rhagic complications.71e73 Emergency intravascular in-
terventions are also associated with a series of relative
risks. Despite these therapies, many patients who have
suffered a stroke remain disabled and require rehabilita-
tion. The increased rate of morbidity and disability from
stroke has prompted clinicians and researchers to explore
more effective and safer treatments, especially for those
patients for which thrombolytic therapy and percutaneous
intravascular interventions are unsuitable. A novel
approach to the treatment of stroke using gene transfer
techniques has potential advantages over classical phar-
macologic therapy.74
Choosing the appropriate genes for treating stroke is a
great challenge for researchers. The following discusses the
various genes that have been tested for the experimental
treatment of stroke. The first are growth factor genes such
as brain-derived neurotrophic factor (BDNF), glial cell line-
derived neurotrophic factor (GDNF), and nerve growth
factor (NGF). BDNF is a neurotrophin that promotes the
survival and growth of developing neurons in vitro,75,76 and
improves motor neuronal function in animal neurological
injury models.77,78 In rats subjected to transient forebrain
ischemia, BDNF was neuroprotective and attenuated
ischemic neuronal injury.79 GDNF has been shown to affect
striatal neurogenesis after rat stroke,8 and acts via the
extracellular glycosylphospatidylinositol-linked receptor,icrobubble destruction in gene therapy: A new tool to cure human
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sine kinase, c-Ret or through a c-Ret-independent mecha-
nism.80 Other groups also reported that GDNF receptor
expression was upregulated in the penumbral areas
following cerebral ischemia in rats, and short-term
neuronal survival was improved by GDNF delivery.81 NGF,
as the name implies, is a neuropeptide primarily involved in
the regulation of growth, maintenance, proliferation, and
survival of certain target neurons. In a rat stroke model,
Andsberg et al showed that intrastriatal delivery of NGF
could moderately mitigate neuronal death following stroke,
which led to detectable functional sparing.82
Anti-apoptosis genes such as Bcl-2 and BCL-w have also
been investigated. Shimazaki et al transferred the Bcl-2
gene into the CA1 pyramidal cell layer of the hippocampus
and found that the application of Bcl-2 both before
ischemia and after ischemia prevented DNA fragmentation
in CA1 neurons.83 Similarly, Okada et al showed that post-
ischemic delivery of the Bcl-2 gene conferred neuro-
protection in gerbil hippocampus.9 Sun et al found that
local intracerebral administration of BCL-w to rat cerebral
cortex and striatum three weeks before stroke resulted in
increased expression of BCL-w in cerebral cortex and
striatal neurons, as well as in astroglia and endothelial
cells. Recipients of BCL-w showed a 30% reduction in infarct
size and a 33e40% improvement in neurological function
compared to control groups.84 These results suggest that
anti-apoptosis gene intervention may be a rational and
effective therapeutic strategy for stroke.
The third group of genes that have been explored are
angiogenesis genes, including VEGF. Many pre-clinical
studies have suggested that VEGF administration following
brain ischemia significantly alleviates neurological deficits
and decreases infarct volume.10,85 For example, Bellomo
et al injected VEGF into the lateral ventricle of gerbils six
or 12 days before ischemia and reported that VEGF gene
therapy significantly improved animal survival and post-
ischemic learning ability as well as delayed neuronal
death in the CA1 area of the hippocampus.86
Lastly, there are also other genes such as Interleukin-1,
neuroglobin and AIP (apoptotic protease activating factor-1
interacting protein) that have been reported to significantly
reduce infarct size and improve functional outcome in focal
cerebral ischemia models by different protective mecha-
nisms after transduction which are still not defined.87e89
However, the therapeutic effects of these genes on stroke
have been reported by only a few research studies and
more experimental evidence is necessary to validate their
efficacy.UTMD gene delivery technique for stroke
UTMD-mediated gene therapy (including delivery of the
VEGF gene) targeting the heart improved myocardial
perfusion and cardiac function after myocardial infarction
in mice and rats.15,16 Ultrasound destruction of gene-loaded
MBs in the ischemic region released the genes into the area.
We therefore hypothesized that delivery of the VEGF
plasmid to the peri-ischemic region of the brain after
infarction could be accomplished with UTMD. We showed
that a transient disruption in the bloodebrain barrier (BBB)Please cite this article in press as: Wu J, Li R-K, Ultrasound-targeted m
diseases, Genes & Diseases (2016), http://dx.doi.org/10.1016/j.gendiwas sufficient to permit transfection of cerebral tissue. We
next evaluated VEGF delivery with UTMD for the treatment
of ischemic stroke in a murine transient middle cerebral
artery occlusion (tMCAO) model.11 Our study demonstrated
that transcranial UTMD is a safe and effective technique for
gene delivery and brain cell transfection after tMCAO in
mice. A single transcranial UTMD treatment resulted in a
transient increase in BBB permeability with no lasting
adverse histological or functional effects. Bioluminescence
imaging after delivery of the luciferase reporter gene
confirmed that gene expression was confined to the tar-
geted region of the brain, and immunostaining for GFP
showed that transfected cells were located in the peri-
infarct region. Our data were corroborated by other
research groups who have also demonstrated gene trans-
fection of normal brain tissue mediated by UTMD.90,91
However, our findings specifically show the beneficial ef-
fect of this technique in a mouse stroke model.11 Over-
expression of the VEGF gene after transcranial UTMD
increased microvessel density, reduced apoptosis,
decreased infarct size, and attenuated the impairment of
neurologic function in mice with ischemic stroke (Fig. 3).
Therefore, this minimally invasive methodology has signif-
icant potential for clinical application.Safety issues and limitations of the UTMD
technique
Medical ultrasound is a commonly used non-invasive tech-
nique for clinical imaging. Following extensive pre-clinical
studies and clinical trials, the Food and Drug Administration
(FDA) approved using MBs in the medical field to enhance
ultrasound imaging to see the lining of the left ventricle of
the heart more clearly and monitor blood flow in tissue or
organs. Ultrasound is generally considered a safe imaging
modality.92 However, ultrasound should not be performed
without a medical indication as previous studies have raised
some safety issues. For example, a study at the Yale School
of Medicine found a small but significant correlation be-
tween prolonged and frequent use of ultrasound and
abnormal neuronal migration in mice.93 Another clinical
study has linked the subtle effects of neurological damage
to ultrasound by showing an increased incidence of left-
handedness in boys (a marker for brain problems when
not hereditary) and speech delays.94e96 Although these
findings were not confirmed in a later follow-up,97 a recent
study with a larger sample of 8865 children established a
statistically significant, though weak association between
ultrasound exposure and being non-right handed later in
life.98 Diagnostic and therapeutic ultrasound equipment is
thus regulated in the United States by the FDA, and
worldwide by other national regulatory agencies. The main
regulated parameters are the mechanical index, a param-
eter associated with the cavitation bio-effect, and the
thermal index, a parameter associated with the tissue
heating bio-effect. The FDA requires that ultrasound
equipment not exceed established limits to ensure safety.
In addition to the safety issues mentioned above, UTMD
has the following limitations: (a) MBs usually do not last
long in circulation and have low circulation residence
times. Therefore, UTMD should be performed at an earlyicrobubble destruction in gene therapy: A new tool to cure human
s.2016.08.001
Fig. 3 VEGF gene delivery by transcranial UTMD. (A) Staining with 2,3,5-triphenyltetrazolium 7 days after UTMD delineated the
infarct area as white (arrows). (B) Mice in the vascular endothelial growth factor (VEGF) group had significantly smaller infarct
areas compared with mice in the phosphate buffered saline (PBS) and empty vector groups (**p < 0.01).
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better than intravenous bolus injection99; (b) Ultrasound
produces more heat with increased frequency. For
example, ultrasound of 3 MHz produced both vigorous
heating (at 3.4 min) and an absolute temperature of 40 C
(at 4 min) at a depth of 2.5 cm, and it was more effective in
heating muscle at this depth than 1 MHz ultrasound.100 Thus
the ultrasonic frequency must be carefully selected and
side effects should be monitored; (c) UTMD could cause
local microvasculature ruptures and hemolysis. When the
UTMD technique is used for tissue repair and regeneration,
the nature of the tissue must be considered. For example,
soft tissue like that of the brain should be treated using
different parameters than harder tissue such as heart
muscle or skeletal muscle.101 The advantage of UTMD for
gene or molecule delivery is repeatability. However,
repeated UTMD could result in tissue damage as multiple
UTMD was associated with brain tissue hemorrhage and a
mild elevation in cardiac troponin I protein release11,16; and
(d) Despite using targeted MBs, the adhesion efficiency is
still low which means a small fraction of injected MBs bind
to the area of interest limiting clinical applicability.102 One
of the strategies to improve MB adhesion is to use dual
targeting. Ferrante et al have used dual agents, mAb
MVCAM.A to target VCAM-1 and a sialyl Lewisx polymer
(PAA-sLex) to target P-selectin, for the purpose of molec-
ular imaging of atherosclerotic plaques. Dual-targeted MBsPlease cite this article in press as: Wu J, Li R-K, Ultrasound-targeted m
diseases, Genes & Diseases (2016), http://dx.doi.org/10.1016/j.gendadhered almost twice as efficiently as single-targeted
MBs.103
Hence, the benefits and risks of UTMD should be care-
fully considered for clinical trials to assess therapeutic gene
delivery. Some circumstances might require more gene
transfers, and the relationship between number of treat-
ments (UTMD) and the degree of microvascular injury will
need to be established. Different MBs may demand
different ultrasonic parameters during gene or molecule
transfection. MBs combined with high energy ultrasound
have been reported to damage cells and tissue.104,105
Therefore, ultrasound energy has to be carefully moni-
tored. Future studies will be required to define the optimal
ultrasound time, frequency, duration and energy to deliver
genes while minimizing tissue damage.Conclusions
In summary, gene therapy has the potential to become an
effective weapon to help fight diseases such as cardiovas-
cular disease, cancer and stroke. UTMD gene therapy can
transduce ischemic myocardium, solid tumors and the brain
to mediate a therapeutic effect. With further development
of technology and research, UTMD could be a promising
non-viral method for targeted gene therapy that may be
useful in across a broad spectrum of human diseases.icrobubble destruction in gene therapy: A new tool to cure human
is.2016.08.001
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